CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.

por Beijnen, J. H., Flora, K. P., Halbert, G. W., Henrar, R. E., Slack, J. A.
Publicado 1995

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

por Danson, S, Ferry, D, Alakhov, V, Margison, J, Kerr, D, Jowle, D, Brampton, M, Halbert, G, Ranson, M
Publicado 2004

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

por Clamp, A R, Blackhall, F H, Vasey, P, Soukop, M, Coleman, R, Halbert, G, Robson, L, Jayson, G C
Publicado 2003

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

por Rustin, G J S, Bradley, C, Galbraith, S, Stratford, M, Loadman, P, Waller, S, Bellenger, K, Gumbrell, L, Folkes, L, Halbert, G
Publicado 2003

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

por Blackhall, F H, Ranson, M, Radford, J A, Hancock, B W, Soukop, M, McGown, A T, Robbins, A, Halbert, G
Publicado 2001

Hormonal impact of the 17α-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

por O'Donnell, A, Judson, I, Dowsett, M, Raynaud, F, Dearnaley, D, Mason, M, Harland, S, Robbins, A, Halbert, G, Nutley, B, Jarman, M
Publicado 2004

The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder

por Qayyum, T, Fyffe, G, Duncan, M, McArdle, P A, Hilmy, M, Orange, C, Halbert, G, Seywright, M, Horgan, P G, Underwood, M A, Edwards, J
Publicado 2012

Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma

por Pritchard-Jones, K, Spendlove, I, Wilton, C, Whelan, J, Weeden, S, Lewis, I, Hale, J, Douglas, C, Pagonis, C, Campbell, B, Alvarez, P, Halbert, G, Durrant, L G
Publicado 2005

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

por Jameson, M B, Thompson, P I, Baguley, B C, Evans, B D, Harvey, V J, Porter, D J, McCrystal, M R, Small, M, Bellenger, K, Gumbrell, L, Halbert, G W, Kestell, P
Publicado 2003

A phase I study of the nitroimidazole hypoxia marker SR4554 using (19)F magnetic resonance spectroscopy

por Lee, C P, Payne, G S, Oregioni, A, Ruddle, R, Tan, S, Raynaud, F I, Eaton, D, Campbell, M J, Cross, K, Halbert, G, Tracy, M, McNamara, J, Seddon, B, Leach, M O, Workman, P, Judson, I
Publicado 2009